drugset
drugset / Trial / NCT03882255

A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State

NCT03882255 ↗

Phase 1 Completed 52 enrolled Janssen Pharmaceutica N.V., Belgium
RandomizedParallel-groupDouble-blindOther

Summary

The primary purpose of this study is to evaluate the effect of the up-titration regimen of ponesimod on heart rate (HR) and other electrocardiogram (ECG) parameters when administrated to healthy adult participants receiving propranolol at steady state.

Timeline

Start
2019-03-20
Primary completion
2019-08-26
Completion
2019-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Ponesimod Small molecule 2 mg Oral
Subject Ponesimod Small molecule 20 mg Oral
Subject Propranolol Small molecule 80 mg Oral

Indications

No indication recorded.